Army tests IV antiviral against Kidney-Damaging hemorrhagic fever
NCT ID NCT04283513
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This phase 2 trial investigates whether intravenous ribavirin (Virazole) can reduce deaths in adults with hemorrhagic fever with renal syndrome (HFRS), a severe viral illness that can cause kidney failure. The study enrolls military-affiliated personnel with probable or suspected HFRS and measures mortality at 10, 14, and 28–60 days, along with tracking side effects. The goal is to determine if this antiviral treatment improves survival in this serious infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IV Ribavirin (Virazole)
- What this could lead to
- If effective, IV ribavirin could become a standard treatment to reduce deaths from HFRS, a serious viral infection affecting kidneys.
- What could go wrong
- This is a small, early-phase trial (50 participants) focused on safety and mortality reduction. The drug may not prove effective or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMORRHAGIC FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Landstuhl Regional Medical Center
Landstuhl, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.